Minimal sequence requirements for oligodeoxyribonucleotides activating human TLR9

Journal of Immunology

Volumn 194, Issue 8, 2015, Pages 3901-3908

  Pohar, Jelka ^a   Krajnik, Alenka Kužnik ^a   Jerala, Roman ^a,b   Benčina, Mojca ^a,b  

^a NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^b EN FIST CENTRE OF EXCELLENCE   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE DERIVATIVE; THYMIDINE DERIVATIVE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BINDING SITE; CELL ACTIVATION; CELL CULTURE; CONTROLLED STUDY; DIMERIZATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOLECULAR RECOGNITION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MOTIF; CHEMISTRY; HEK293 CELL LINE; IMMUNOLOGY; PROTEIN MULTIMERIZATION;

B-LYMPHOCYTES; BINDING SITES; HEK293 CELLS; HUMANS; OLIGODEOXYRIBONUCLEOTIDES; PROTEIN MULTIMERIZATION; TOLL-LIKE RECEPTOR 9;

EID: 84927663615     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402755     Document Type: Article

References (44)

1. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
2. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760.
3. Hornung, V., S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdörfer, T. Giese, S. Endres, and G. Hartmann. 2002. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168:4531-4537.
4. Moseman, A. P., E. A. Moseman, S. Schworer, I. Smirnova, T. Volkova, U. Von Andrian, and A. Poltorak. 2013. Mannose receptor 1 mediates cellular uptake and endosomal delivery of CpG-motif containing oligodeoxynucleotides. J. Immunol. 191:5615-5624.
5. Sivori, S., S. Carlomagno, M. Falco, E. Romeo, L. Moretta, and A. Moretta. 2011. Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood 117:4284-4292.
6. Lahoud, M. H., F. Ahmet, J.-G. Zhang, S. Meuter, A. N. Policheni, S. Kitsoulis, C.-N. Lee, M. O'Keeffe, L. C. Sullivan, A. G. Brooks, et al. 2012. DEC-205 is a cell surface receptor for Cp Goligonucleotides. Proc. Natl. Acad. Sci. USA 109:16270-16275.
7. Gursel, M., D. M. Klinman, and I. Gursel. 2013. Plasmacytoid dendritic cell response to CpG ODN correlates with CXCL16 expression and is inhibited by ox-LDL. Mediators Inflamm. 2013:312590.
8. Krieg, A. M. 2006. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5:471-484.
9. Hartmann, G., G. J. Weiner, and A. M. Krieg. 1999. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 96:9305-9310.
10. Hanagata, N. 2012. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int. J. Nanomedicine 7:2181-2195.
11. Klinman, D. M., A. K. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg. 1996. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 93:2879-2883.
12. Hartmann, G., and A. M. Krieg. 2000. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164:944-953.
13. Vollmer, J., M. Jurk, U. Samulowitz, G. Lipford, A. Forsbach, M. Wüllner, S. Tluk, H. Hartmann, A. Kritzler, C. Müller, et al. 2004. CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. J. Endotoxin Res. 10:431-438.
14. Guiducci, C., G. Ott, J. H. Chan, E. Damon, C. Calacsan, T. Matray, K.-D. Lee, R. L. Coffman, and F. J. Barrat. 2006. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J. Exp. Med. 203:1999-2008.
15. Hartmann, G., J. Battiany, H. Poeck, M. Wagner, M. Kerkmann, N. Lubenow, S. Rothenfusser, and S. Endres. 2003. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur. J. Immunol. 33:1633-1641.
16. Vollmer, J., R. Weeratna, P. Payette, M. Jurk, C. Schetter, M. Laucht, T. Wader, S. Tluk, M. Liu, H. L. Davis, and A. M. Krieg. 2004. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34:251-262.
17. Samulowitz, U., M. Weber, R. Weeratna, E. Uhlmann, B. Noll, A. M. Krieg, and J. Vollmer. 2010. A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. Oligonucleotides 20:93-101.
18. Struthers, M., A. J. Bett, T. Wisniewski, S. A. Dubey, M. Precopio, W. Jiang, Z. Sun, H. Wang, I. Nowak, M. R. Putta, et al. 2010. Synthesis and immunological activities of novel agonists of toll-like receptor 9. Cell. Immunol. 263:105-113.
19. Yu, D., M. R. Putta, L. Bhagat, M. Dai, D. Wang, A. F. Trombino, T. Sullivan, E. R. Kandimalla, and S. Agrawal. 2008. Impact of secondary structure of tolllike receptor 9 agonists on interferon alpha induction. Antimicrob. Agents Chemother. 52:4320-4325.
20. Kandimalla, E. R., L. Bhagat, Y.-P. Cong, R. K. Pandey, D. Yu, Q. Zhao, and S. Agrawal. 2003. Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Biochem. Biophys. Res. Commun. 306:948-953.
21. Agrawal, S., and E. R. Kandimalla. 2007. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem. Soc. Trans. 35:1461-1467.
22. Cong, Y.-P., S. S. Song, L. Bhagat, R. K. Pandey, D. Yu, E. R. Kandimalla, and S. Agrawal. 2003. Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells. Biochem. Biophys. Res. Commun. 310:1133-1139.
23. Klinman, D. M., and D. Currie. 2003. Hierarchical recognition of CpG motifs expressed by immunostimulatory oligodeoxynucleotides. Clin. Exp. Immunol. 133:227-232.
24. Yi, A. K., M. Chang, D. W. Peckham, A. M. Krieg, and R. F. Ashman. 1998. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol. 160:5898-5906.
25. Rankin, R., R. Pontarollo, X. Ioannou, A. M. Krieg, R. Hecker, L. A. Babiuk, and S. Van Drunen Littel-van Den Hurk. 2001. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 11:333-340.
26. Haas, T., J. Metzger, F. Schmitz, A. Heit, T. Müller, E. Latz, and H. Wagner. 2008. The DNA sugar backbone 29 deoxyribose determines toll-like receptor 9 activation. Immunity 28:315-323.
27. Gay, N. J., and M. Gangloff. 2007. Structure and function of Toll receptors and their ligands. Annu. Rev. Biochem. 76:141-165.
28. Marshall, J. D., K. Fearon, C. Abbate, S. Subramanian, P. Yee, J. Gregorio, R. L. Coffman, and G. Van Nest. 2003. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukoc. Biol. 73:781-792.
29. Meng, W., T. Yamazaki, Y. Nishida, and N. Hanagata. 2011. Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Tolllike receptor 9 agonists. BMC Biotechnol. 11:88.
30. Jurk, M., B. Schulte, A. Kritzler, B. Noll, E. Uhlmann, T. Wader, C. Schetter, A. M. Krieg, and J. Vollmer. 2004. C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology 209:141-154.
31. Hartmann, G., R. D. Weeratna, Z. K. Ballas, P. Payette, S. Blackwell, I. Suparto, W. L. Rasmussen, M. Waldschmidt, D. Sajuthi, R. H. Purcell, et al. 2000. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164:1617-1624.
32. Latz, E., A. Verma, A. Visintin, M. Gong, C. M. Sirois, D. C. G. Klein, B. G. Monks, C. J. McKnight, M. S. Lamphier, W. P. Duprex, et al. 2007. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat. Immunol. 8:772-779.
33. Ashman, R. F., J. A. Goeken, E. Latz, and P. Lenert. 2011. Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding. Int. Immunol. 23:203-214.
34. Kindrachuk, J., J. E. Potter, R. Brownlie, A. D. Ficzycz, P. J. Griebel, N. Mookherjee, G. K. Mutwiri, L. A. Babiuk, and S. Napper. 2007. Nucleic acids exert a sequence-independent cooperative effect on sequence-dependent activation of Toll-like receptor 9. J. Biol. Chem. 282:13944-13953.
35. Rutz, M., J. Metzger, T. Gellert, P. Luppa, G. B. Lipford, H. Wagner, and S. Bauer. 2004. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequenceand pH-dependent manner. Eur. J. Immunol. 34:2541-2550.
36. Kerkmann, M., L. T. Costa, C. Richter, S. Rothenfusser, J. Battiany, V. Hornung, J. Johnson, S. Englert, T. Ketterer, W. Heckl, et al. 2005. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. J. Biol. Chem. 280:8086-8093.
37. Keniry, M. A. 2000-2001. Quadruplex structures in nucleic acids. Biopolymers 56:123-146.
38. Dalpke, A. H., S. Zimmermann, I. Albrecht, and K. Heeg. 2002. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 106:102-112.
39. Gürsel, M., D. Verthelyi, I. Gürsel, K. J. Ishii, and D. M. Klinman. 2002. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J. Leukoc. Biol. 71:813-820.
40. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772-777.
41. Chinnathambi, S., S. Chen, S. Ganesan, and N. Hanagata. 2012. Binding mode of CpG oligodeoxynucleotides to nanoparticles regulates bifurcated cytokine induction via Toll-like receptor 9. Sci Rep 2:534.
42. Suwarti, S., T. Yamazaki, C. Svetlana, and N. Hanagata. 2013. Recognition of CpG oligodeoxynucleotides by human Toll-like receptor 9 and subsequent cytokine induction. Biochem. Biophys. Res. Commun. 430:1234-1239.
43. Baek, K. H., S. J. Ha, and Y. C. Sung. 2001. A novel function of phosphorothioate oligodeoxynucleotides as chemoattractants for primary macrophages. J. Immunol. 167:2847-2854.
44. Wagner, H. 2011. New vistas on TLR9 activation. Eur. J. Immunol. 41:2814-2816.